Navigating the Pandemic: How will COVID-19 change R&D?

COVID-19 has put the biopharma industry into a tailspin – big pharma, biotech and small startups are all emerging in the development of a treatment and vaccine for this pandemic. Will COVID-19 change the current R&D landscape and create a new norm for the biopharma industry?

Joan Koerber-Walker
President and CEO, Arizona BioIndustry Association (AZBio)

Brian Neman
Co-Founder and CEO, Sanguine

Todd Parsley
Director of Preclinical Research, Infectious Diseases at Noble Life Sciences Inc

Chris Moore, PhD
Senior Director, Immunology, Arbutus Biopharma, Inc.